CytomX Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
CytomX Therapeutics, Inc. (CTMX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 2.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-03-16
- CytomX Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was 2.70%, a 98.89% decline from fiscal 2023.
- CytomX Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 242.70%, a 10012.50% increase from fiscal 2022.
- CytomX Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 2.40%, a 20.00% increase from fiscal 2021.
- CytomX Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 2.00%, a 69.70% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 2.70% 10-K · filed 2026-03-16 | |
| 2023-12-31 | 242.70% 10-K · filed 2024-03-11 | |
| 2022-12-31 | 2.40% 10-K · filed 2024-03-11 | |
| 2021-12-31 | 2.00% 10-K/A · filed 2023-03-27 | 2.80% 10-K · filed 2022-03-01 |
| 2020-12-31 | 6.60% 10-K/A · filed 2023-03-27 | 11.00% 10-K · filed 2021-02-24 |
| 2019-12-31 | 1.90% 10-K/A · filed 2023-03-27 | 2.50% 10-K · filed 2020-02-27 |
| 2018-12-31 | 6.20% 10-K · filed 2021-02-24 | |
| 2017-12-31 | 2.70% 10-K · filed 2020-02-27 | |
| 2016-12-31 | 2.20% 10-K · filed 2019-02-27 | |
| 2015-12-31 | 0.80% 10-K · filed 2018-03-07 | |
| 2014-12-31 | 1.30% 10-K · filed 2017-03-02 | |
| 2013-12-31 | 3.30% 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |